£490.00

It has never been this cheap. We have no record of a lower price.

£490 today · cheaper than every other day in the last 3 months

Exocrine Pancreatic Insufficiency Therapeutics Outlook 2023-2028

View at Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 79 days · 79 data points (no recent data)

Historical
Generating forecast…
£490.00 £465.50 £475.30 £485.10 £494.90 £504.70 £514.50 11 August 2026 30 August 2026 19 September 2026 08 October 2026 28 October 2026
View at Amazon ↗

Price data last checked 12 day(s) ago - will refresh soon

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 79 days • 1 price levels

Days at Price
79 days 0 20 40 59 79 £490 Days at Price

Price Analysis

Most common price: £490 (79 days, 100.0%)

Price range: £490 - £490

Price levels: 1 different prices over 79 days

Description

This comprehensive market study provides a detailed outlook for exocrine pancreatic insufficiency therapeutics across the United States from 2023 to 2028. The report focuses on latent demand, providing potential industry earnings (P.I.E.) estimates for 10,833 US zip codes. By analyzing these specific geographic locations, the data helps users identify market opportunities and scale their operations effectively. Each zip code includes comparative benchmarks, showing its percent share relative to both its specific state and the United States as a whole. This statistical approach offers a clear way to gauge market value at a granular level, making it a practical resource for distribution planning and sales strategy development.

Key Features

Provides latent demand outlook and potential industry earnings estimates for exocrine pancreatic insufficiency therapeutics through 2028.

Includes detailed data across 10,833 specific US zip codes to support highly localized market analysis.

Offers comparative benchmarks by reporting the percent share of each zip code relative to its state and the entire United States.

Supports distribution and sales strategies through granular statistical data and geographic market segmentation.

Delivers precise potential industry earnings (P.I.E.) estimates measured in millions of U.S. dollars.

Product Specifications

Format
paperback
Domain
Amazon UK
Release Date
09 January 2023
Listed Since
27 January 2023

Similar Products You Might Like

The 2023-2028 Outlook for Exocrine Pancreatic Insufficiency Therapeutics in China
99% match

The 2023-2028 Outlook for Exocrine Pancreatic Insufficiency Therapeutics in China

£495.00 02 Sep 2026
The 2023-2028 Outlook for Exocrine Pancreatic Insufficiency Therapeutics in Japan
99% match

The 2023-2028 Outlook for Exocrine Pancreatic Insufficiency Therapeutics in Japan

£495.00 31 Oct 2026
Exocrine Pancreatic Insufficiency Therapeutics India Outlook
98% match

Exocrine Pancreatic Insufficiency Therapeutics India Outlook

£515.00 28 Oct 2026
Exocrine Pancreatic Insufficiency Therapeutics Outlook 2023-2028
98% match

Exocrine Pancreatic Insufficiency Therapeutics Outlook 2023-2028

£520.00 29 Aug 2026
Pancreatic Cancer Drug Outlook: Africa & Middle East Study
97% match

Pancreatic Cancer Drug Outlook: Africa & Middle East Study

£325.00 07 Nov 2026
Pancreatic Cancer Drug Outlook in Latin America 2013-2018
97% match

Pancreatic Cancer Drug Outlook in Latin America 2013-2018

£325.00 26 Aug 2026
Pancreatic Cancer Drug Outlook 2013-2018 - North America
97% match

Pancreatic Cancer Drug Outlook 2013-2018 - North America

£325.00 25 Aug 2026
Pancreatic Cancer Drug Outlook in Europe 2013-2018 Study
96% match

Pancreatic Cancer Drug Outlook in Europe 2013-2018 Study

£325.00 07 Nov 2026
The 2011-2016 Outlook for Pancreatic Cancer Drugs in The Middle East
96% match

The 2011-2016 Outlook for Pancreatic Cancer Drugs in The Middle East

£325.00 26 Aug 2026
The 2021-2026 World Outlook for Pancreatic Cancer Drugs
96% match

The 2021-2026 World Outlook for Pancreatic Cancer Drugs

£795.00 04 Nov 2026
Pancreatic Cancer Drug Outlook in Africa 2011-2016 Study
96% match

Pancreatic Cancer Drug Outlook in Africa 2011-2016 Study

£325.00 26 Aug 2026
The 2016-2021 Outlook for Pancreatic Cancer Drugs in the United States
96% match

The 2016-2021 Outlook for Pancreatic Cancer Drugs in the United States

£595.00 08 Nov 2026
The 2013-2018 Outlook for Pancreatic Cancer Drugs in Oceana
96% match

The 2013-2018 Outlook for Pancreatic Cancer Drugs in Oceana

£325.00 25 Aug 2026
Multidisciplinary Management of Acute and Chronic Pancreatitis
96% match

Multidisciplinary Management of Acute and Chronic Pancreatitis

IntechOpen

£119.00 24 Sep 2026
Peptides and Heparin for Diabetes Outlook 2023-2028 Study
95% match

Peptides and Heparin for Diabetes Outlook 2023-2028 Study

£490.00 03 Sep 2026
The 2013-2018 Outlook for Dipeptidyl Peptidase IV (DPP-IV) Inhibitors in the United States
95% match

The 2013-2018 Outlook for Dipeptidyl Peptidase IV (DPP-IV) Inhibitors in the United States

£495.00 31 Oct 2026
2023-2028 Pen Insulin Syringes US Zip Code Market Outlook
95% match

2023-2028 Pen Insulin Syringes US Zip Code Market Outlook

£490.00 26 Aug 2026
Chronic Pancreatitis
95% match

Chronic Pancreatitis

IntechOpen

£114.00 18 Sep 2026
DPP-IV Inhibitors in Europe 2013-2018 Econometric Study
95% match

DPP-IV Inhibitors in Europe 2013-2018 Econometric Study

£325.00 12 Sep 2026
The 2013-2018 Outlook for Dipeptidyl Peptidase IV (DPP-IV) Inhibitors in Japan
95% match

The 2013-2018 Outlook for Dipeptidyl Peptidase IV (DPP-IV) Inhibitors in Japan

£495.00 08 Sep 2026
Chronic Pancreatitis: From Basic Research to Clinical Treatment
95% match

Chronic Pancreatitis: From Basic Research to Clinical Treatment

Springer

£99.99 12 Sep 2026
The 2013-2018 Outlook for Dipeptidyl Peptidase IV (DPP-IV) Inhibitors in Greater China
95% match

The 2013-2018 Outlook for Dipeptidyl Peptidase IV (DPP-IV) Inhibitors in Greater China

£495.00 04 Nov 2026
The 2013-2018 Outlook for Dipeptidyl Peptidase IV (DPP-IV) Inhibitors in India
95% match

The 2013-2018 Outlook for Dipeptidyl Peptidase IV (DPP-IV) Inhibitors in India

£495.00 30 Oct 2026
Pancreatic Islet Cell Regeneration and Growth: Proceedings of a Diabetes Institute Conference Held in Norfolk, Virginia, June 22-23, 1991: v. 321 (Advances in Experimental Medicine and Biology)
95% match

Pancreatic Islet Cell Regeneration and Growth: Proceedings of a Diabetes Institute Conference Held in Norfolk, Virginia, June 22-23, 1991: v. 321 (Advances in Experimental Medicine and Biology)

Springer

£94.00 09 Sep 2026